NCT01254864 2025-01-27
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
8 trialsNCT00570700 2019-02-26
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer
University of California, Irvine
Phase 2 Completed
NCT01260688 2018-08-08
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
National Cancer Institute (NCI)
Phase 2 Completed
NCT00860158 2018-03-14
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00744497 2016-10-17
READY
Bristol-Myers Squibb
Phase 3 Completed
NCT00918385 2014-10-29
ARS
Duke University
Phase 2 Terminated
NCT00439270 2014-03-28
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00385580 2013-04-30
Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer
Bristol-Myers Squibb
Phase 2 Completed